What is Zocor (simvastatin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Zocor?

Zocor (simvastatin) is a prescription cholesterol-lowering medication that belongs to the class of drugs called HMG-CoA reductase inhibitors (statins), used primarily to reduce cardiovascular risk and treat elevated cholesterol levels. 1

Mechanism of Action

Simvastatin is a prodrug that is converted to its active form (simvastatin acid) after administration. It works by:

  • Competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis 2, 1
  • Increasing LDL receptor expression on liver cells, which enhances removal of LDL cholesterol from the bloodstream 2
  • Reducing production of very-low-density lipoproteins (VLDL) 1

Clinical Uses

Zocor is FDA-approved for multiple indications 1:

Cardiovascular Risk Reduction:

  • Reduces risk of death from heart disease
  • Lowers risk of heart attacks and strokes
  • Decreases need for arterial revascularization procedures
  • Particularly beneficial in patients with known cardiovascular disease, diabetes, or high cardiovascular risk

Cholesterol Management:

  • Lowers LDL ("bad") cholesterol by 35-45% at standard doses 2
  • Treats primary hyperlipidemia and heterozygous familial hypercholesterolemia (in adults and children ≥10 years)
  • Manages primary dysbetalipoproteinemia
  • Reduces triglycerides
  • Modestly increases HDL ("good") cholesterol by 5-15% 2

Available Formulations

Zocor tablets are available in 10 mg, 20 mg, and 40 mg strengths for once-daily oral administration 1. The 5 mg and 80 mg strengths are no longer marketed due to safety concerns (the 80 mg dose carries increased myopathy risk) 1.

Critical Drug Interactions

Simvastatin has the highest number of clinically significant drug interactions among statins because it undergoes extensive CYP3A4 metabolism 2. Key interactions requiring dose limitations or avoidance include:

  • Avoid completely: Gemfibrozil, conivaptan, strong CYP3A4 inhibitors (certain antifungals, HIV protease inhibitors, clarithromycin, erythromycin) 2, 1
  • Limit to 10 mg daily: Diltiazem, verapamil, dronedarone 2
  • Limit to 20 mg daily: Amiodarone, amlodipine, ranolazine, bempedoic acid 2
  • Monitor closely: Colchicine (increased myopathy risk) 2

Important Safety Considerations

Myopathy and Rhabdomyolysis Risk:

  • Most serious adverse effect, though rare 1
  • Risk increases with higher doses, advanced age (≥65 years), renal impairment, and drug interactions 1
  • Chinese patients may have higher myopathy risk 1
  • Patients must report unexplained muscle pain, tenderness, or weakness immediately 1

Contraindications:

  • Active liver disease or decompensated cirrhosis 1
  • Pregnancy and breastfeeding 1
  • Concurrent use with strong CYP3A4 inhibitors 1

Hepatic Monitoring:

  • Can cause liver enzyme elevations 1
  • Patients should report fatigue, dark urine, jaundice, or right upper abdominal discomfort 1

Clinical Evidence

Simvastatin has robust cardiovascular outcomes data from landmark trials 3, 4:

  • The Scandinavian Simvastatin Survival Study (4S) was the first cholesterol-lowering trial to demonstrate reduced all-cause mortality (30% reduction) 3, 4
  • The Heart Protection Study (HPS) showed benefits across diverse patient populations including women, elderly, diabetics, and those with baseline LDL below population average 4

Dosing Considerations

  • Expected LDL-C reduction: 18-55% depending on dose 2
  • Maximum effect typically achieved within 4 weeks 1
  • For severe renal impairment (CrCl 15-29 mL/min), start with 5 mg daily 1
  • Geriatric patients require cautious dosing due to increased myopathy risk 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.